Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that triggers coronavirus disease 2019 (COVID-19). This latest SARS disease was first identified during an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. The World Health Organization first declared this to be a global health emergency in January 2020. By March, COVID-19 rocketed to a global pandemic—the first such designation since 2009’s H1N1 influenza pandemic.

As of mid-March 2020, global confirmed cases of COVID-19 have surpassed 184,000 with over 7,400 deaths worldwide. While there are fewer new cases in China, containment efforts have so far failed to reduce the rate of reported cases in many countries. The virus is continuing its global spread with the distinct possibility of becoming a new endemic coronavirus within the human population.

As an active supporter of the scientific community that is collaborating today on COVID-19 solutions, BIOVIA, Dassault Systèmes is proud to offer BIOVIA Discovery Studio. This world-class life sciences modeling and simulation environment brings together over 30 years of peer-reviewed research and world-class in silico techniques. It provides researchers with a complete toolset for use from target identification through to lead optimization, including tools for biologics design and analysis, classical simulations, structure- and fragment-based design, virtual ligand screening, as well as ADME and toxicity prediction.

As part of Dassault Systèmes’ corporate social responsibility, BIOVIA is pleased to offer academic researchers six months of complimentary access to BIOVIA Discovery Studio to assist them in the search for rapid, safe and effective therapeutic drug candidates against the SARS-CoV-2 virus. If you are an academic researcher in this field, please submit the form for review in order to arrange a software license and download.

Also, Follow BIOVIA on LinkedIn for upcoming blog posts on other topics pertaining to BIOVIA Discovery Studio’s usefulness in COVID-19 research, including protein structure determination with homology modeling, virtual screening/drug repurposing and pharmacophore modeling for lead identification.

This offer is limited to one per research group, and the Primary Investigator (PI) should make this application. If you are not the PI, you need to provide confirmation that your PI approves this request. This is so that we do not have a subsequent request from the same research group. Using your professional email address would also facilitate your request.



In addition, you will be requested to submit a brief one-paragraph description of your SARS-CoV-2 related research and how Discovery Studio may be used to help accelerate your work. You will also need to provide evidence of a prior research track record (published articles and ongoing research) in this field to confirm your eligibility.



Due to the extremely high number of requests we are receiving there may be a delay in our response.